ResearchSafe

PE 22-28 and TREK-1 blockade, is anyone else watching this space?

Posted by midwest_scientist in Research & News - 4 points, 6 comments.

I have been going down the rabbit hole on PE 22-28 lately. It is a spadin-derived peptide that blocks the TREK-1 potassium channel, and the preclinical angle is fast-acting antidepressant effects plus neurogenesis. You can read the profile here: /peptides/pe-22-28.

Honestly what caught my attention is the mechanism. TREK-1 is a background potassium channel, so blocking it basically makes neurons more excitable and pushes serotonergic signalling. The idea that you could get something that acts faster than SSRIs is appealing on paper, but I keep reminding myself this is all animal data so far. No human safety data, no established dosing. That part makes me cautious even though I am usually the first to try things.

I have not tried PE 22-28 myself. The lack of any human pharmacokinetics data is honestly the thing that stops me. A short half-life peptide with unknown human metabolism is not something I want to guess at.

What I find promising though is the neuroplasticity angle, not just mood. If TREK-1 blockade genuinely increases synaptogenesis, there could be interesting applications beyond depression. Stroke recovery research is mentioned in the profile and that seems worth tracking.

Is anyone here actually following the TREK-1 research or tried spadin-derived compounds? Curious what your impression is of the safety gap between animal and human use here.

Comments

  • curious_scientist: The stroke recovery angle is what jumped out at me too. I spent years in rehab settings and the neuroplasticity window after a stroke is something we desperately need better tools for. Existing approaches are slow and inconsistent. But yeah, the pharmacokinetics gap is real. A peptide with no human half-life data, no established route, no metabolism info, that is a lot of unknowns stacked on top of each other. At least with something like Semax there is some human use history to lean on. PE 22-
  • sleep_coastal: The PK gap is what keeps me from going near it too. Anecdotally I have gone down the preclinical-only rabbit hole before and it is a different animal when you actually put something in your body with zero human metabolism data. Semax at least has real-world history you can triangulate from. PE 22-28 feels like watching from the sidelines for now. The stroke recovery angle is genuinely interesting though, that neuroplasticity window is underserved.
  • greg_codes: Yeah the PK gap is what puts me off too. Semax at least has decades of human exposure in russia to lean on even if the data quality is sketchy. PE 22-28 is basically a mechanism in search of a delivery method? Like what route even makes sense for a CNS-targeted peptide with zero human half-life data. Intranasal seems the obvious guess but that is still a guess. Keen to see if anyone has actually tracked anything real on it.
  • midwest_scientist: That "mechanism in search of a delivery method" framing is honestly exactly how I think about it. The Semax comparison is fair, even with the sketchy data quality you at least have something. With PE 22-28 you are just guessing. Intranasal is where my head goes too because that is the route the spadin-derived work seems to point toward, but I have not seen anyone actually post a real log with it. The half-life question is the real wall. If it clears in minutes you might get a brief window of ef
  • midwest_scientist: Yeah the Semax comparison is exactly right, that is the difference between something with a couple decades of human use behind it and a peptide that has only been in mice. Honestly I keep almost pulling the trigger and then the metabolism question pulls me back. The stroke recovery angle is what I find most compelling too. That acute neuroplasticity window is so narrow and there is basically nothing good for it right now. I wonder if anyone is even working toward human trials on PE 22-28 for th
  • midwest_scientist: I agree with you about the Semax comparison. It feels much safer because we actually know how people react to it. The stroke recovery part is definitely the most exciting bit for me, but the lack of human data makes it feel like we are jumping into the dark. Do you think we will see human trials for TREK-1 blockers soon, or is this staying in animal models for a long time?

Community discussion - research and educational context only. Not medical advice.